These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 29099421

  • 1. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
    Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, Dhali GK, Chowdhury A, Das K.
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
    [Abstract] [Full Text] [Related]

  • 2. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
    Schepke M, Wiest R, Flacke S, Heller J, Stoffel-Wagner B, Herold T, Ghauri M, Sauerbruch T.
    Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
    [Abstract] [Full Text] [Related]

  • 3. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
    Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P.
    J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
    [Abstract] [Full Text] [Related]

  • 4. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
    Baik SK, Park DH, Kim MY, Choi YJ, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ.
    J Gastroenterol; 2003 May; 38(12):1150-4. PubMed ID: 14714252
    [Abstract] [Full Text] [Related]

  • 5. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
    Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-Valdecasas JC, Navasa M, García-Pagán JC, Bosch J.
    Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A, Hernández-Gea V, Bosch J.
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [Abstract] [Full Text] [Related]

  • 7. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C.
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [Abstract] [Full Text] [Related]

  • 8. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J.
    Lancet; 2019 Apr 20; 393(10181):1597-1608. PubMed ID: 30910320
    [Abstract] [Full Text] [Related]

  • 9. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
    Lim YL, Kim MY, Jang YO, Baik SK, Kwon SO.
    Gut Liver; 2017 Sep 15; 11(5):702-710. PubMed ID: 28651304
    [Abstract] [Full Text] [Related]

  • 10. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J.
    Hepatology; 2003 Apr 15; 37(4):902-8. PubMed ID: 12668985
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J.
    J Hepatol; 2009 Aug 15; 51(2):279-87. PubMed ID: 19501930
    [Abstract] [Full Text] [Related]

  • 12. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J.
    Hepatology; 1999 Jul 15; 30(1):79-83. PubMed ID: 10385642
    [Abstract] [Full Text] [Related]

  • 13. Carvedilol or propranolol in portal hypertension? A randomized comparison.
    Hobolth L, Møller S, Grønbæk H, Roelsgaard K, Bendtsen F, Feldager Hansen E.
    Scand J Gastroenterol; 2012 Apr 15; 47(4):467-74. PubMed ID: 22401315
    [Abstract] [Full Text] [Related]

  • 14. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.
    Kim JH, Kim JM, Cho YZ, Na JH, Kim HS, Kim HA, Kang HW, Baik SK, Kwon SO, Cha SH, Kim YJ, Kim MY.
    Clin Mol Hepatol; 2014 Dec 15; 20(4):376-83. PubMed ID: 25548744
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J.
    Gastroenterology; 2009 May 15; 136(5):1651-8. PubMed ID: 19208350
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ, IDN-6556-14 Investigators(‡).
    J Hepatol; 2020 May 15; 72(5):885-895. PubMed ID: 31870950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.